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http://www.biomedcentral.com/1471-2407/14/756RESEARCH ARTICLE Open AccessAnti-proliferative but not anti-angiogenic tyrosine
kinase inhibitors enrich for cancer stem cells in
soft tissue sarcoma
Robert J Canter1*, Erik Ames2, Stephanie Mac2, Steven K Grossenbacher2, Mingyi Chen3, Chin-Shang Li4,
Dariusz Borys3, Rachel C Smith2, Joe Tellez2, Thomas J Sayers5, Arta M Monjazeb6 and William J Murphy7Abstract
Background: Increasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following
conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as
tyrosine kinase inhibitors (TKIs). We hypothesized that TKIs would have differential effects on CSC populations
depending on their mechanism of action (anti-proliferative vs. anti-angiogenic).
Methods: We exposed human sarcoma cell lines to sorafenib, regorafenib, and pazopanib and assessed cell
viability and expression of CSC markers (ALDH, CD24, CD44, and CD133). We evaluated survival and CSC phenotype
in mice harboring sarcoma metastases after TKI therapy. We exposed dissociated primary sarcoma tumors to
sorafenib, regorafenib, and pazopanib, and we used tissue microarray (TMA) and primary sarcoma samples to
evaluate the frequency and intensity of CSC markers after neoadjuvant therapy with sorafenib and pazopanib.
Parametric and non-parametric statistical analyses were performed as appropriate.
Results: After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and
regorafenib were cytotoxic to sarcoma cell lines (P < 0.05), with a corresponding 1.4 – 2.8 fold increase in ALDHbright cells
from baseline (P < 0.05). In contrast, we observed negligible effects on viability and CSC sub-populations with pazopanib.
At low doses, there was progressive CSC enrichment in vitro after longer term exposure to sorafenib although
the anti-proliferative effects were attenuated. In vivo, sorafenib improved median survival by 11 days (P < 0.05),
but enriched ALDHbright cells 2.5 – 2.8 fold (P < 0.05). Analysis of primary human sarcoma samples revealed direct
cytotoxicity following exposure to sorafenib and regorafenib with a corresponding increase in ALDHbright cells (P < 0.05).
Again, negligible effects from pazopanib were observed. TMA analysis of archived specimens from sarcoma patients
treated with sorafenib demonstrated significant enrichment for ALDHbright cells in the post-treatment resection specimen
(P < 0.05), whereas clinical specimens obtained longitudinally from a patient treated with pazopanib showed no
enrichment for ALDHbright cells (P > 0.05).
Conclusions: Anti-proliferative TKIs appear to enrich for sarcoma CSCs while anti-angiogenic TKIs do not. The rational
selection of targeted therapies for sarcoma patients may benefit from an awareness of the differential impact of TKIs
on CSC populations.
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The cancer stem cell (CSC) hypothesis postulates that
CSCs, also referred to as tumor-initiating cells, repre-
sent a small proportion of malignant cells in the overall
tumor bulk [1,2]. It is these typically quiescent cells
which are resistant to conventional cytotoxic cancer
therapies and which are able to repopulate tumors even
after apparent complete response to chemotherapy
and/or radiotherapy (RT) [3-5]. The presence of CSC
subpopulations has been identified in nearly all human
malignancies, and mounting studies of CSC engraft-
ment in long term culture and immune-compromised
mice have validated the CSC phenotype [6-8]. More-
over, genetic lineage tracing studies have provided pro-
vocative evidence for the existence of CSCs in a
hierarchy of asymmetric cell division and tumor re-
population in models of squamous cell carcinoma, in-
testinal adenomas, and GBM. These studies provide the
highest level evidence to date that CSCs are clinically
and biologically significant [3,9,10].
Numerous CSC markers have been identified and char-
acterized, including cell surface markers such as CD24,
CD44, and CD133, and the intracellular enzyme aldehyde
dehydrogenase (ALDH), among others [1,8,11,12]. Al-
though investigators have observed the expression of CSC
markers to vary depending on experimental conditions
and tumor type, ALDH has been consistently identified as
a CSC marker in breast cancer and prostate cancer, and
levels of ALDHbright cells have been observed to predict
worse oncologic outcome in numerous human cancers,
including soft tissue sarcoma (STS) [7,13-18]. Awad et al.,
for example, identified an ALDHbright subpopulation of
Ewing’s sarcoma cells which was able to stimulate long
term colony outgrowth, form tumor xenografts in immu-
nodeficient mice, and resist chemotherapy treatment [19].
Although CSCs are considered resistant to standard
anti-cancer therapies such as chemotherapy and RT,
few studies have examined the effects of tyrosine kinase
inhibitors (TKIs) on CSCs, particularly the differential
effects of TKIs depending on their mechanism of action.
Sorafenib is a pleotropic TKI which exerts its activity pri-
marily by direct effects on cell proliferation via inhibition
of C-Raf and B-Raf [20]. Sorafenib is FDA-approved for
the treatment of advanced renal, liver, and thyroid cancer
[21], and Phase II studies of sorafenib have demonstrated
activity and clinical benefit for patients with metastatic
STS [22,23]. A recently completed Phase I trial demon-
strated safety and preliminary data for activity in locally
advanced extremity STS [24]. Regorafenib is a second gen-
eration multi-kinase inhibitor with activity and mechan-
ism of action similar to sorafenib [25]. Regorafenib is
approved for the treatment of metastatic colon cancer and
advanced gastrointestinal stromal tumors [26]. In contrast,
pazopanib is a potent inhibitor of angiogenesis [27]. In arecently completed international phase III trial for patients
with metastatic STS, pazopanib reduced the risk of tumor
progression or death approximately 70%, leading to its
approval for STS by the FDA in 2013 [28]. Pazopanib
is also approved for the treatment of patients with advanced
renal cell carcinoma [29].
Given the increasing clinical use of targeted therapies
such as TKIs in clinical oncology including STS as well
as the evidence suggesting that specific tyrosine kinases
may promote the CSC phenotype [30], we sought to de-
termine the effects of TKIs on whole tumor bulk and
CSC populations in diverse models of STS. We hypothe-
sized that there would be differential effects of TKIs on
CSC populations depending on their mechanism of ac-
tion and that enrichment for sarcoma CSCs would be
more prevalent with anti-proliferative TKIs rather than
anti-angiogenic TKIs.
Methods
Tumor cell lines
Human sarcoma cell lines (A673 Ewing’s sarcoma,
SW-982 synovial sarcoma, and SK-LMS leiomyosarcoma)
were obtained from the American Type Culture Collec-
tion (Manassas, VA) and maintained in the recom-
mended tissue culture medium supplemented with 10%
heat-inactivated fetal calf serum, L-glutamine, penicillin
G, streptomycin, amphotericin, and gentamycin.
Materials
Sorafenib p-Tosylate salt, regorafenib, and pazopanib free
base were obtained from LC Laboratories (Woburn, MA).
For in vitro experiments, compounds were dissolved in a
stock solution of 100% DMSO and then diluted to final
concentration of 0.2% DMSO. Stock solutions were
replenished every 4–6 weeks per manufacturer’s rec-
ommendations. For in vivo experiments, sorafenib was
protected from light, dissolved in 10% DMSO, 10%
cremaphor, and 80% sterile PBS, and sterile-filtered
through 0.2 μM pores (Cole-Parmer, Chicago, IL). Daily
intraperitoneal (i.p.) injections were administered using
fresh sorafenib. Placebo animals received i.p. injections
containing 10% DMSO, 10% cremaphor, and 80% sterile
PBS.
ALDEFLUOR™ assay and flow cytometry
ALDEFLUOR™ expression (STEMCELL Technologies,
Vancouver, BC, Canada) was determined according to
the manufacturers’ instructions using diethylaminoben-
zaldehyde (DEAB) to inhibit ALDH activity and to con-
trol for background fluorescence (Additional file 1:
Figure S1). Pacific Blue anti-human CD45 (HI30) and
7-AAD were purchased from BD Biosciences (San Jose,
CA). PE-Cy7 anti-human CD24 and Pacific Blue anti-
human CD44 were purchased from BioLegend (San
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Miltenyi Biotec (Auburn, CA). All samples were acquired
on an LSR Fortessa with HTS (BD Biosciences, San
Jose, CA) and analyzed with FlowJo software (TreeStar,
Ashland, OR).Animals and tumor cell implantation
Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice,
aged 7 – 8 weeks, were obtained from The Jackson La-
boratory (Bar Harbor, ME) and housed under specific
pathogen-free conditions. For subcutaneous/flank tumor
inoculation, cells were harvested from 80% confluent cell
culture conditions, counted, and resuspended in sterile
PBS at a concentration of 25 × 106/mL. A total of 5 × 106
cells in 200-μL aliquots were then injected subcutaneously
into the dorsal-lateral aspect of the flank. Tumors were
allowed to grow to 3 – 5 mm in maximal dimension prior
to initiating treatment. For intravenous tumor inoculation,
cells were resuspended in sterile PBS at a concentration of
2 × 106/mL, and a total of 2 × 106 cells in 1-mL aliquots
were then injected by tail vein. Tumors were allowed to
grow for approximately 3 weeks by which time multiple
lung and liver metastases were reproducibly visible on
necropsy studies prior to initiating treatment. All experi-
mental protocols were approved by the UC Davis Institu-
tional Animal Care and Use Committee.Xenograft tumor evaluation
Mice were euthanized at indicated time points. Lung
and liver metastases were excised and manually dissoci-
ated in PBS to create an homogenous slurry. Collagenase
I (1 mg/mL) and DNAase (0.1 mg/mL) were dissolved in
2% BSA (weight/volume), filtered using a 0.22 μM ster-
ile filter (Pall Life Sciences), and mixed with tumor
slurry. Samples were incubated at 37o C for one hour,
filtered sequentially using 100 μM, 70 μM, and 40 μM
filters (BD Biosciences, ), centrifuged at 1200 rpm for
5 minutes, resuspended in PBS, and counted using a
Coulter Counter. Repeat centrifugation was performed,
and tumor cells were resuspended at PBS at 1 – 2 × 106
cells per mL for flow cytometry.Histology and immunohistochemistry
Xenograft tumor samples were fixed for 24 – 48 hours
in 10% formalin and then transferred to 90% ethanol.
Hematoxylin and eosin (H&E) slides were reviewed in a
blinded fashion by a pathologist (M.C./D.B.). Percent
histologically intact tumor and percent necrotic tumor
were scored per slide, and mean percent tumor necrosis
was calculated for the entire specimen, excluding non-
neoplastic tissue. Approximately 5 – 10 H & E slides
were examined per animal.Evaluation of primary sarcoma samples
Primary STS and benign tumor resections (SA-0689,
CCS0015-012, CCS0015-010, SA-0624, and SA-0751)
were obtained immediately after surgical excision through
the UC Davis Comprehensive Cancer Center Bioreposi-
tory. Informed consent was obtained from all patients
before tissue procurement under the auspices of the In-
stitutional Review Board of UC Davis. Primary STS
tumor samples were processed into single cell suspen-
sions for CSC phenotyping and ex vivo exposure to
TKIs as described above. CD45 negative selection was
used to exclude nonneoplastic myeloid and lymphoid
cells from analysis, and 7AAD viability dye was used to
exclude dead cells.
Evaluation of archived clinical sarcoma samples
Tissue microarrays (TMA) were constructed using
formalin-fixed, paraffin-embedded clinical sarcoma speci-
mens obtained by the UC Davis Cancer Center Bioreposi-
tory (CCBR) Core Facility. Eight patients were previously
treated on a phase I clinical trial protocol (UCDCC#216,
NCT) using neoadjuvant sorafenib and RT for locally ad-
vanced extremity STS prior to resection with curative in-
tent [24]. Eight STS patients who were treated with
primary surgical resection (without neoadjuvant sorafenib
and RT) were used as controls. IRB approval for this retro-
spective analysis of prospectively collected STS tumor tis-
sue was obtained from the Institutional Review Board of
UC Davis.
Following antigen retrieval and blocking, TMA sec-
tions (4 μm) were immunostained using a commercially-
available purified mouse anti-human ALDH1 antibody
(BD Transduction Laboratories, San Jose, CA) with ap-
propriate positive and negative controls. We used the
avidin–biotin complex method (DAKO) with 3,3’-diami-
nobenzidine (DAB) for visualization. Stained slides were
reviewed by a pathologist (M.C.) who was blinded to the
clinical outcome and scored for percentage and intensity
of ALDH1-positive cells. The product of the percentage
of cells staining positive and the staining intensity was
then calculated as described previously.
Statistical considerations
Summary statistics were reported as mean ± standard
error with median (range) where appropriate. Categor-
ical variables were compared using a chi-squared test.
Parametric continuous variables were compared using
an independent samples t-test. Non-parametric con-
tinuous variables were compared using the Mann–
Whitney U test. For comparison of more than 2 groups,
statistical significance was determined using a one-way
ANOVA followed by a Bonferroni multiple-group com-
parison test. Survival curves were evaluated using the
Kaplan-Meier method. ALDH scores before and after
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t-test. Statistical analyses were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC) and Graph-Pad
Prism 5. Significance was set at P <0.05.
Results
ALDHbright sarcoma cells display CSC properties
We first validated the CSC phenotype of ALDHbright
A673 Ewing’s sarcoma cells. After sorting cells by FACS
into ALDHbright and ALDHdim sub-populations, we ob-
served ALDHbright cells were able to sustain long term
survival in vitro (data not shown) and to form tumor
xenografts in NSG mice (Additional file 2: Figure S2).
ALDHbright cells established tumors faster and were
more rapidly fatal than ALDHdim cells (P < 0.05). We
also observed marked differences in tumor growth and
volume between ALDHbright and ALDHdim populations on
visual inspection at necropsy (Additional file 1: Figure S1B)
and using T1- and T2-weighted MRI (Additional file 1:
Figure S1C). In contrast, we observed CD24, CD44, and
CD133 to be variably expressed in our sarcoma cell lines,
and we found that these markers did not reliably correlate
with the CSC phenotype (Additional file 1: Figure S1D).
Dose dependent TKI effects in vitro
As depicted in Figure 1, we tested the dose-dependent ef-
fects of overnight exposure to sorafenib, pazopanib, and
regorafenib on three human sarcoma cell lines. All three
cell lines (Figure 1A–C) were sensitive to the cell killing
effects of sorafenib at doses ranging from 8–64 μM,
while pazopanib had no effect on cell viability and rego-
rafenib demonstrated cell killing comparable to sorafe-
nib (Figure 1G).
Concomitant with its anti-proliferative effects, sorafe-
nib also enriched for ALDHbright sarcoma CSCs in all
three cell lines (Figure 1D–F). Interestingly, we ob-
served the greatest CSC enrichment at lower doses of
sorafenib than those which caused the greatest anti-
viability effects. In A673 cells, for example, the ALDHb-
right population increased from 9.5 ± 0.7% at baseline to
13.3 ± 1.3% at 4 μM (1.4X increase, P < 0.001) before
dropping to 1.1 ± 1.1% at 32 μM, likely representing in-
duction of cell death for both CSC and non-CSC
population at higher doses. Similarly, sorafenib expos-
ure enriched the ALDHbright population in SK-LMS
cells (Figure 1E) from 6.8 ± 2.4% at baseline to a peak
of 19.3 ± 1.5% at 4 μM sorafenib (2.8X increase, P < 0.001).
We also observed sorafenib enrichment for the ALDHbright
sub-population in SW982 cells (Figure 1 F) with the
proportion rising from 48.1 ± 6.3% at 0 μM sorafenib
to a peak of 76.7 ± 4.2% at 16 μM sorafenib (1.6X in-
crease, P < 0.001). Compared to sorafenib, we did not
observe any significant changes in the ALDHbright popula-
tions of these cell lines following exposure to pazopanib,while regorafenib demonstrated similar CSC enrichment
to sorafenib in SW982 cells (Figure 1H).
Time dependent effects in vitro
We then wanted to determine if longer exposure to these
TKIs increased the sensitivity of these cell lines to cell kill-
ing or CSC enrichment. At 4 μM sorafenib (Figure 2A),
A673 cells remained insensitive to sorafenib, even with
3 day exposure to the drug. In contrast, culture at 32 μM
sorafenib led to a cumulative loss of 87.6 ± 1.8% viable
cells on day 2 (P < 0.001) and 95.5 ± 1.4% on day 3 (P <
0.001). With SK-LMS cells (Figure 2B), we also observed
relatively negligible changes in viability following 3-day ex-
posure to 4 μM sorafenib, aside from a transient decrease
in viability compared to controls on day 2. Similar to
A673 cells, at high dose sorafenib (32 μM), we observed
progressive decreases in SK-LMS cell viability over time,
decreasing to 73.7 ± 4.9% on day 1, 47.1 ± 6.5% on day 2,
and 34.4 ± 6.7% on day 3, respectively (P < 0.001). The re-
sults of 3-day culture with pazopanib and regorafenib
(Figure 2E) paralleled those we observed with overnight
culture. There was no effect of 4 μM pazopanib on SK-
LMS viability after 3 days, while 32 μM regorafenib was
comparable to sorafenib with a cumulative drop in viabil-
ity to 52.1 ± 3.5% (P < 0.001).
We also observed differences in the time-dependent ef-
fects of sorafenib on CSC enrichment in vitro. In A673
cells (Figure 2C), we observed a progressive enrichment in
ALDHbright cells with long term exposure to 4 μM sorafe-
nib, reaching 39.4 ± 2.8% on day 3 (P < 0.001). Conversely,
at 32 μM sorafenib, the percentage of ALDHbright cells de-
clined to 0.5 ± 0.9% and 0 ± 0% after 2 and 3 days of soraf-
enib exposure, respectively (P < 0.001). In SK-LMS cells
(Figure 2D), there was a cumulative enrichment in
ALDHbright cells at day 2 and day 3 of exposure to 4 and
32 μM sorafenib, respectively, whereas there was no sig-
nificant change in the percentage of ALDHbright cells over
3 days among the vehicle-treated controls.
From these data, we concluded that longer exposure
to low dose sorafenib led to persistent CSC enrichment
without any increase in anti-proliferative effects, suggest-
ing a possible mechanism of resistance to the drug at
lower doses. High dose sorafenib was effective at indu-
cing cell death in both CSC and non-CSC populations in
A673 cells, but in SK-LMS cells there was less sensitivity
to the drug and a corresponding progressive enrichment
in ALDHbright cells, also suggesting that enrichment in
CSC populations may correlate with drug resistance.
Sorafenib exerts anti-proliferative effects in vivo while
enriching for sarcoma CSCs
We then tested the effects of sorafenib in an in vivo model.
Injection of A673 cells into NSG mice by tail vein reprodu-
cibly produced lung and liver metastases after 21 days. We
Figure 1 Dose-dependent effects of TKIs on sarcoma cell line viability and CSC enrichment in vitro. A673 (Ewing’s sarcoma), SK-LMS
(leiomyosarcoma), and SW982 (synovial sarcoma) cells were exposed to increasing doses of sorafenib, pazopanib, and regorafenib for 18 – 24 hours.
SSChi cells were then analyzed by flow cytometry using 7AAD as a cell viability stain, and ALDH expression was assessed using ALDEFLUOR™ reagents.
Total cell counts and cell percentages relative to parent populations were determined. A – C. Cell viability was significantly inhibited in all cell lines at
increasing doses of sorafenib, while no significant differences with pazopanib were observed. D – F. Significant enrichment of ALDHbright
sarcoma populations was observed in all cell lines following exposure to increasing doses of sorafenib, while negligible differences were
observed with pazopanib. G. Sorafenib and regorafenib exert anti-proliferative effects on SW982 cells, although sorafenib is more potent
than regorafenib. H. Sorafenib and regorafenib show similar enrichment for ALDHbright CSCs. In each panel, a representative experiment of
3 replicates is shown. * P < 0.05, ** P < 0.01, and *** P < 0.001 via one-way ANOVA with Tukey’s post-test compared to dose level 0.
Canter et al. BMC Cancer 2014, 14:756 Page 5 of 13
http://www.biomedcentral.com/1471-2407/14/756then treated mice in groups of 4–5 with daily injections of
i.p. sorafenib or vehicle until tissues were harvested or sur-
vival studies were completed (Figure 3A). Previous studies
have observed in vivo effects of sorafenib at doses ranging
from 30–100 mg/kg [20,31]. Although we observed a linear
relationship between sorafenib dose in vivo and tumor
growth delay, 100 mg/kg was toxic to approximately 10%
of animals. Therefore, we opted to use 75 mg/kg as the
in vivo dose of sorafenib.
As shown in Figure 3B, we observed that sorafenib
prolonged survival in vivo by a median of 11 days from
18 days post-initiation of treatment to 29 days (P = 0.03).
Histological evaluation of tumors after sorafenib treatmentrevealed a statistically significant increase in tumor ne-
crosis (Figure 3C). On day 7 post-treatment, percent
tumor necrosis was 6.0 ± 2.2% in placebo-treated animals
vs. 32.0 ± 2.7% in sorafenib-treated animals (P < 0.001).
There was also a significant increase in percent tumor
necrosis in sorafenib-treated animals on day 12 post-
treatment (P < 0.001). Figure3D shows representative
micrographs of tumor histology from placebo-treated
and sorafenib-treated animals, respectively.
As shown in Figure 3E, tumor cell proliferation as
measured by Ki-67 staining was significantly higher in
placebo-treated than sorafenib-treated animals. In placebo-
treated animals, the percentage of Ki-67 positive cells was
Figure 2 Time-dependent effects of TKIs on sarcoma cell viability and CSC enrichment in vitro. A673, SK-LMS, and SW982 cells were
exposed to low- and high-dose sorafenib for 1 – 3 days. SSChi cells were then analyzed by flow cytometry using 7AAD, and ALDH expression was
assessed using ALDEFLUOR™. A. A673 cell viability was unaffected over 3 days of culture at 4 μM sorafenib, while 32 μM sorafenib demonstrated
significant reduction in cell viability over time. B. At 4 μM sorafenib, SK-LMS cell viability overall paralleled that of controls except for a transient
decrease on day 2. In contrast, at 32 μM sorafenib, there was ongoing significant reduction in cell viability over time, although cells were less
sensitive to sorafenib than A673 cells. C. At 4 μM sorafenib, A673 cells showed progressive significant enrichment in ALDHbright sub-populations
during 3 days of culture. In contrast, at 32 μM sorafenib, there is significant reduction in ALDHbright sub-populations on days 2 and 3. D. At 4 and
32 μM sorafenib, SK-LMS ALDHbright sub-populations were elevated after 1 day of sorafenib culture and continued to show enrichment in ALDHbright
cells on days 2 and 3. E. SK-LMS cell viability was unaffected over 3 days of culture at 32 μM pazopanib, while sorafenib and regorafenib demonstrated
similar anti-viability effects. For each panel, a representative experiment of 3 replicates is shown. *P < 0.05, **P < 0.01, and ***P < 0.001 via one-way
ANOVA with Tukey’s post-test.
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respectively. In contrast, in sorafenib-treated animals,
the percentage of Ki-67 positive cells was 51 ± 4% and
53 ± 10% on days 7 and 12 post-treatment, respectively
(P < 0.001). Non-viable, necrotic areas were excluded
from the calculation of Ki-67 staining.
We then evaluated A673 xenografts for changes in
ALDHbright populations after sorafenib and placebotreatment. On day 7 post-treatment (Figure 3G), we ob-
served the ALDHbright sub-population to be significantly
higher in sorafenib-treated tumors than placebo-treated
tumors (P < 0.001). Similarly, on day 12 post-treatment
(Figure 3H), we observed the ALDHbright sub-population
to be higher in the sorafenib-treated animals than
placebo-treated ones, 0.72 ± 0.08% vs. 0.25 ± 0.09%, re-
spectively (P < 0.001). Although the absolute differences in
Figure 3 Effects of sorafenib on A673 xenografts in vivo. A. Schema depicts experimental design in vivo. Sarcoma cells were infused by tail vein on
day 0. Xenografts were allowed to develop for 21 days, and mice were then randomized to i.p. injections of placebo versus sorafenib (75 mg/kg) x 21 days
(or until tumor harvest). B. Mice treated with sorafenib survived significantly longer than placebo-treated mice (median survival post-treatment 29 days vs.
18 days, P = 0.03 by log-rank test). C. Sorafenib-treated metastatic lung tumors demonstrated significantly greater tumor necrosis than placebo-treated tumors
at indicated time points (P < 0.001 by paired t-test at both time points). D. Representative images of placebo- and sorafenib-treated tumors stained with
hematoxylin and eosin (H&E) on treatment day 12. Placebo-treated tumors remain highly cellular and mitotically active with minimal tumor necrosis, while
sorafenib-treated tumors show necrosis (**) and inflammation (*) surrounding areas of viable tumor. E. Sorafenib-treated metastatic lung tumors demonstrated
significantly decreased numbers of Ki67 positive cells than placebo-treated tumors at day 7 and day 12 of treatment (P < 0.001 by paired t-test at both time
points). F. Representative images of placebo- and sorafenib-treated tumors stained for Ki67 on treatment day 7. Non-necrotic, viable areas of
sorafenib-treated tumors demonstrate fewer proliferating cells than placebo-treated tumors. Boxed areas are depicted at higher magnification.
G – H. Metastatic lung tumors harvested at indicated time points demonstrate statistically greater ALDHbright CSCs than placebo-treated
controls (P < 0.001 by paired t-test). For all panels, representative data from 2 – 3 experiments are shown.
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treated animals were relatively modest, these differences
nevertheless represented 2.5–2.9 fold enrichment in
the CSC population at both time points.Based on these data, we concluded that sorafenib
exerts anti-proliferative effects in vivo while simultan-
eously enriching for CSCs, suggesting a preferential anti-
proliferative effect on the non-CSCs.
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but enriches for sarcoma CSCs
We then analyzed the effects of TKIs on tumor cells
freshly isolated from STS specimens (and benign soft tis-
sue tumors) obtained at the time of surgical resection.
There was marked patient to patient heterogeneity of
tumor cells and the percentage of ALDHbright cells de-
tected at baseline (Figure 4A–D). Leiomyosarcoma cells
from patient SA-0689 (Figure 4A) decreased in viability
from 61.3 ± 2.6% at baseline to 44.3 ± 0.2% and 39.7 ± 0.4%
at 32 μM and 64 μM sorafenib, respectively (P < 0.001)
with a corresponding enrichment in ALDHbright cells from
10.4 ± 0.5% at baseline to a peak of 15.0 ± 0.7% at 8 μM so-
rafenib (P < 0.001). For patient CCS0015-010 (Figure 4B),
sorafenib decreased the viability of dedifferentiated lipo-
sarcoma cells from 26.9 ± 0.5% at baseline to 11.2 ± 0.6%
at 32 μM sorafenib (P < 0.01) and 6.6 ± 0.3% at 64 μM so-
rafenib (P < 0.001), respectively. There was simultaneous
enrichment for the ALDHbright sub-population which in-
creased from 24.9 ± 0.8% at baseline to 42.4 ± 1.6% at
64 μM sorafenib (P < 0.001).
Leiomyosarcoma cells from patient CCS0015-012
(Figure 4B) were highly sensitive to sorafenib ex vivo
with a dose-dependent decrease in viability from 90.5 ±
0.3% at baseline to 18.2 ± 1.3% at 64 μM sorafenib
(P < 0.001). These tumor cells demonstrated intermediate
sensitivity to regorafenib, while there was no significant
change in viability following pazopanib exposure. Simul-
taneously, there was a corresponding enrichment in
CCS0015-012 ALDHbright cells following exposure to
both sorafenib and regorafenib. Interestingly, similar to
our in vitro experiments, CSC enrichment following
sorafenib peaked at lower doses of sorafenib (16 μM)
and then dropped at higher doses whereas CSC enrich-
ment following regorafenib remained elevated at higher
doses. We then tested a benign leiomyoma (Figure 4D) to
ascertain whether some of these effects could be attributed
to the ex vivo digestion process. We observed no signifi-
cant change in cell viability or the ALDHbright population
following sorafenib exposure.
Despite the variability between patient samples, we
concluded from these data that sorafenib was directly
cytotoxic to human primary sarcomas ex vivo with a
corresponding increase in ALDHbright cells, and our
ex vivo results with pazopanib and regorafenib corre-
lated with our results in vitro.
Preoperative sorafenib enriches for CSCs in clinical
sarcoma specimens
We then analyzed ALDH1 staining by IHC from archived
specimens of STS patients. We created a TMA using rep-
licate cores of tumor tissue obtained from STS patients
previously treated with neoadjuvant sorafenib and con-
formal RT on a Phase I clinical trial for patients withlocally advanced disease amenable to treatment with cura-
tive intent (Clinical Trial Information: NCT#00805727/
UCDCC#216) [24]. Patients underwent a core biopsy to
establish the diagnosis of STS (pre-treatment) followed by
5–6 weeks of preoperative treatment with sorafenib at one
of two doses (200 mg bid and 200/400 daily) with concur-
rent RT. Surgical resection was performed 4–6 weeks fol-
lowing completion of neoadjuvant therapy.
Using matched patient tissue before and after sorafe-
nib therapy, we observed increases in the ALDH1 score
among all patients (Figure 5A). Moreover, the mean
ALDH1 score increased significantly from 31 ± 14 pre-
treatment to 101 ± 18 post-treatment (P = 0.003). We
then evaluated ALDH1 staining intensity in a control co-
hort of STS patients who declined participation or were
ineligible for NCT#00805727/UCDCC#216. These pa-
tients underwent diagnostic biopsy followed by definitive
surgical resection without preoperative therapy. As
shown in Figure 5C, using matched tissue from these pa-
tients, we observed no difference in the mean ALDH1
score from tumor tissue obtained at biopsy versus tissue
obtained at surgical resection (biopsy mean ALDH1
score 46 ± 34 vs. resection mean score 44 ± 27, P = 0.86).
We then examined paired samples of tissue from a pa-
tient with metastatic STS who was treated with pazopanib
and underwent surgical resection before and after treat-
ment (Figure 5E). There was no significant difference in
the percentage of ALDHbright cells present in the specimen
after pazopanib treatment, providing additional evidence
from STS patients that sorafenib enriches for ALDHbright
sarcoma CSCs while pazopanib does not.
Discussion
Accumulating evidence suggests that CSCs exist as a
sub-population of quiescent cells within the dominant
tumor bulk of heterogeneous tumor cells [1,12]. These
typically dormant cells are considered resistant to
standard anti-cancer therapies such as chemotherapy
and RT, and they appear capable of self-renewal and
differentiation [5,19,32,33], suggesting that CSCs are re-
sponsible for tumor repopulation after bulk tumor has
been destroyed [3].
Numerous studies have focused on characterizing the
behavior and phenotype of CSCs. Much attention has
been devoted to demonstrating that the expression of
cell surface markers, such as CD24, CD44, and CD133,
and the activity of the intracellular enzyme ALDH con-
sistently predict the CSC phenotype. In addition, the
presence of CSCs, in general, and ALDH expression, in
particular, has been shown to predict worse prognosis in
numerous human cancers, such as breast, prostate, and
kidney [13,14,17]. Despite this attention to the signifi-
cance of CSCs, relatively few studies have examined the
differences in anti-proliferative versus anti-angiogenic
Figure 4 Effects of TKIs on viability and CSC enrichment in short term ex vivo culture of resected clinical sarcoma tumors. A. (Left)
High power view shows moderately differentiated recurrent renal vein leiomyosarcoma from patient SA-0689. Freshly digested tumor cells were
exposed to increasing doses of sorafenib for 16 – 18 hours and then analyzed by flow cytometry for viability and ALDH expression using 7AAD
and ALDEFLUOR™, respectively. (Middle) Ex vivo tumor cell viability was significantly inhibited at ≥16 μM of sorafenib. (Right) Significant
enrichment of ALDHbright sarcoma cells was observed at sorafenib doses of 8 and 16 μM. B. (Left) High power view shows highly cellular,
non-lipogenic dedifferentiated liposarcoma from patient CCS0015-010, confirmed by MDM2 overexpression. (Middle) Sorafenib significantly
decreases ex vivo tumor viability at 32 and 64 μM, while simultaneously enriching for ALDHbright sarcoma cells doses ≥64 μM (Right). C.
(Left) High power view shows poorly-differentiated high grade leiomyosarcoma from patient CCS0015-012 exposed to sorafenib, regorafenib, and
pazopanib. (Middle) Cell viability was significantly inhibited at ≥16 μM of sorafenib and regorafenib, while no significant differences were observed
following pazopanib exposure. (Right) Significant enrichment of ALDHbright sarcoma cells was observed following sorafenib and regorafenib exposure,
while negligible differences were observed with pazopanib. D. (Left) High power view shows benign leiomyoma from patient SA-0624. No significant
effects on cell viability (Middle) nor on ALDHbright CSCs (Right) were observed following exposure to increasing doses of sorafenib. All experiments
were performed in triplicate. *P < 0.05, **P < 0.01, and *** P < 0.001 via one-way ANOVA with Tukey’s post-test compared to dose level 0.
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Figure 5 ALDH1 expression in clinical specimens of sarcoma patients treated with preoperative sorafenib or pazopanib prior to
surgical resection. A. Increases in ALDH1 staining intensity among soft tissue sarcoma patients treated with neoadjuvant sorafenib and conformal
radiotherapy on a Phase I trial (Clinical Trial Information: NCT#00805727/UCDCC#216). B. Representative photomicrographs of ALDH1 expression from a
patient pre- (top) and post-treatment (bottom) evaluated on tissue microarray. Three cores per patient were analyzed. Boxed areas are depicted at higher
magnification. C. Negligible effects in ALDH1 staining intensity among soft tissue sarcoma patients sarcoma ineligible for NCT#00805727/UCDCC#216
who underwent diagnostic biopsy followed by definitive surgical resection without preoperative therapy. D. Representative photomicrographs of ALDH1
expression from a patient pre- (top) and post-treatment (bottom) from a tissue microarray created from formalin-fixed, paraffin-embedded specimens of
patients with soft tissue sarcoma treated with a biopsy followed by definitive surgical resection without preoperative therapy. Three cores per patient
were analyzed. Boxed areas are depicted at higher magnification. E. High power view shows high grade undifferentiated pleomorphic sarcoma from
patient SA-0751 treated clinically with pazopanib for metastatic sarcoma. (Middle) Flow cytometry reveals no significant difference in ALDHbright cells from
fresh tissue evaluated before and after pazopanib. (Right) Representative flow cytometry plots of ALDH expression are shown. ALDH scores before and
after treatment were analyzed using the two-sided paired t-test. All experiments were performed in triplicate.
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time in cell culture, xenograft models, or clinical speci-
mens, particularly for STS.
In this study, we demonstrate that sorafenib and re-
gorafenib, but not pazopanib, exert significant anti-
proliferative effects while simultaneously enriching for
CSCs in multiple models of STS, including primary sar-
coma cells freshly derived from surgical specimens. Inaddition, we observe enrichment of ALDH1-stained cells
in matched tumor-specimens obtained before and after
neoadjuvant therapy with sorafenib and RT, whereas there
was no evidence of CSC enrichment following clinical
treatment with pazopanib. Although CSCs are widely
believed to be resistant to conventional cytotoxic ther-
apies, such as chemotherapy and RT, there are relatively
few studies which demonstrate similar effects with anti-
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ited data evaluating the differences on CSC enrichment
between various TKIs.
Our study reinforces the concept that anti-proliferative
therapies enrich for the CSC population in solid malig-
nancies and that anti-proliferative TKIs may exert dis-
tinct anti-tumor strategies than anti-angiogenic ones. A
major strength of our study is the substantial amount of
data obtained from STS patients, including fresh STS
specimens procured at the time of surgical resection as
well as retrospectively from archived tumor specimens.
These data emphasize the translational relevance of our
work which suggests that CSC enrichment following TKI
therapy with sorafenib may be a mechanism of tumor re-
sistance. Consequently, we hypothesize that sustained and
durable anti-sarcoma therapies will require concomitant
targeting of CSCs.
These data also reinforce the broader concept that
standard anti-proliferative therapies, including TKIs, tar-
get the proliferating non-CSCs while sparing, or possibly
even promoting, the repopulation of CSCs. Our data also
support the hypothesis that CSCs are a mechanism of re-
sistance to standard anti-proliferative therapies since elim-
ination of non-CSCs parallels the enrichment of CSCs.
Although we demonstrate a consistent pattern for the
effects on sorafenib (distinct from pazopanib) on STS in
diverse pre-clinical and human models, it is important to
acknowledge several limitations of our study. Although
the majority of STS subtypes share a common mesenchy-
mal origin, STS are a heterogenous group of malignancies,
and there is clearly a variation in ALDH expression from
subtype to subtype as well as depending on the cell cul-
ture conditions. Despite this variability in ALDH expres-
sion, we focused on ALDH activity as a CSC marker since
we could validate the phenotype of ALDHbright CSCs. In
contrast, similar to Chen et al., we observed that CD133
and CD44 did not reliably validate the CSC phenotype
[34]. However, the variability of marker expression among
CSCs depending on culture conditions as well as tumor
histology does imply that we may have to adapt the
techniques necessary to identify and target sarcoma
CSCs by subtype and reinforces the concept of some
critics that ALDH and other cell surface molecules only
correlate with the CSC phenotype rather than causally
mediate it [12,35].
In addition, the majority of our pre-clinical data was
obtained from a Ewing’s sarcoma cell line (A673). This
STS subtype is known to share many phenotypic proper-
ties with neuro-ectodermal cells [36]. Consequently, it is
possible that our results with this cell line are biased by
the overlap of A673 cells with neural progenitor tissue,
which are known to harbor pluripotent stem cells [37].
Finally, our data from archived STS specimens treated
on a neoadjuvant clinical protocol including sorafenib isconfounded by the addition of RT to the treatment regi-
men. Although there is significant enrichment after so-
rafenib/RT compared to no treatment, it is conceivable
that some, or the majority, of these effects is secondary
to RT or the combination of sorafenib and RT, rather
than sorafenib alone.Conclusion
In summary, we demonstrate that in diverse sarcoma
models, including extensive clinical sarcoma specimens,
sorafenib exerts significant anti-proliferative effects while
simultaneously enriching for CSCs, and pazopanib does
not. These data indicate that TKIs have differential ef-
fects on CSC populations depending on their mechan-
ism of action. Taken together, our results suggest that
CSC enrichment following anti-proliferative TKI therapy
is an apparent mechanism of tumor resistance. Therefore,
sustained anti-sarcoma therapies may require concomitant
targeting of CSCs.Additional files
Additional file 1: Representative Flow Cytometry Plots of ALDH
Expression A. SW982 cells in vitro are shown. (Left)
Diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH, is used
to control for background fluorescence. (Middle) Vehicle control. (Right)
Sorafenib 16 uM. B. A673 in vivo tumors harvested on treatment day 7
are shown. (Left) DEAB background fluorescence. (Middle) Placebo-treated
controls. (Right) Sorafenib 75 mg/kg.
Additional file 2: Figure S1. Validation of ALDH as a CSC marker in
A673 sarcoma cells. A. A673 cells were sorted by flow cytometry into
ALDHbright and ALDHdim populations. 2 × 105 purified cells were implanted
subcutaneously into contralateral flanks of NSG mice (N = 4) and allowed to
grow. ALDHbright cells established tumors faster and were more rapidly fatal.
*P < 0.05. B. Representative photograph showing difference in tumor
formation between ALDHbright and ALDHdim A673 sarcoma cells sorted by
flow cytometry and implanted subcutaneously in NSG mice.
C. Representative T1- and T2-weighted MRI images demonstrating
difference in tumor formation between ALDHbright and ALDHdim A673
sarcoma cells sorted by flow cytometry and implanted subcutaneously
in NSG mice. D. Expression of CSC cell surface markers and ALDH in
representative STS cell lines.
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